Literature DB >> 15164334

Effect of chenodeoxycholic acid on 11beta-hydroxysteroid dehydrogenase in various target tissues.

David J Morris1, Graham W Souness, Syed A Latif, Matthew P Hardy, Andrew S Brem.   

Abstract

Glucocorticoids are metabolized by isoforms of the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD). There is some controversy concerning the bile acid, chenodeoxycholic acid (CDCA), as a potential endogenously produced inhibitor of 11beta-HSD. The present experiments were designed to determine the relative specificity of CDCA for both isoforms of 11beta-HSD and to assess the biological relevance of inhibition in vascular tissue. IC(50) values (concentrations which inhibit 50% of the enzyme reaction) were calculated using rat liver microsomes as a source of 11beta-HSD1 dehydrogenase, Leydig cells for 11beta-HSD1 dehydrogenase and reductase, aorta for 11beta-HSD1 dehydrogenase and reductase, and sheep kidney for 11beta-HSD2 dehydrogenase. In each case, CDCA functioned as a potent inhibitor of 11beta-HSD1 dehydrogenase with IC(50) values of ranging from 0.2 to 7 micromol/L in contrast to 37 to 200 micromol/L for 11beta-HSD1 reductase. CDCA exhibited relatively weak inhibitory activity against 11beta-HSD2 from sheep kidney with an IC(50) of 70 micromol/L. The effect of CDCA on vascular contraction was studied in aortic rings isolated from Spague-Dawley rats incubated in medium containing corticosterone 10 nmol/L +/- CDCA (1 micromol/L) for 24 hours. Rings were stimulated with graded concentrations of phenylephrine (PE) (10 nmol/L, 100 nmol/L, and 1 micromol/L). Rings exposed to corticosterone and CDCA consistently demonstrated a greater contractile response at lower doses of PE (63% at PE 10 nmol/L, P <.001; 20% at PE 100 nmol/L, P <.025; and 10% at PE 1 micromol/L, not significant [NS]) compared to control preparations incubated with cortiosterone alone. These studies demonstrate (1) that CDCA preferentially affects 11beta-HSD1 dehydrogenase; (2) CDCA does inhibit 11beta-HSD2 dehydrogenase and 11beta-HSD1 reductase but only at high(er) concentrations exceeding 70 micromol/L and 37 micromol/L, respectively; and (3) inhibition of 11beta-HSD1 dehydrogenase in aortic rings by CDCA (1 micromol/L) enhances the contractile response of corticosterone plus PE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164334     DOI: 10.1016/j.metabol.2003.12.027

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

1.  Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-adrenal axis in obstructive jaundice.

Authors:  Alison D McNeilly; David P Macfarlane; Emmett O'Flaherty; Dawn E Livingstone; Tijana Mitić; Kirsty M McConnell; Scott M McKenzie; Eleanor Davies; Rebecca M Reynolds; Helle C Thiesson; Ole Skøtt; Brian R Walker; Ruth Andrew
Journal:  J Hepatol       Date:  2010-03-04       Impact factor: 25.083

Review 2.  Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling?

Authors:  Marine Baptissart; Aurelie Vega; Emmanuelle Martinot; Silvère Baron; Jean-Marc A Lobaccaro; David H Volle
Journal:  Cell Mol Life Sci       Date:  2013-06-20       Impact factor: 9.261

3.  The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome.

Authors:  Minghan Wang
Journal:  Nutr Metab (Lond)       Date:  2005-02-02       Impact factor: 4.169

4.  Hypercortisolism in patients with cholestasis is associated with disease severity.

Authors:  Verena Theiler-Schwetz; Hansjörg Schlager; Barbara Obermayer-Pietsch; Tatjana Stojakovic; Günter Fauler; Peter Fickert; Gernot Zollner
Journal:  BMC Gastroenterol       Date:  2021-12-07       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.